Review



lapc-4 blank cells  (Tree Star Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Tree Star Inc lapc-4 blank cells
    The VEGFR-2 expression in prostate cancer (PrCa) cell lines measured by flow cytometry. The percentage of cell counts are from the same gate of top positive cells in fluorescent intensity in the three PrCa cell lines. Sample groups: Anti-r 2nd Ab only, the controls engaging with Alexa488 anti-rabbit secondary antibody only; Anti-h 2nd Ab only, the controls engaging with Alexa488 anti-human secondary antibody only; 55B11 as 1st Ab, the samples engaging with rabbit anti-human 55B11 as the primary antibody; Df-R as 1st Ab, the samples engaging with deferoxamine-conjugated Ramucirumab as the primary antibody (for PC-3 cell line, n = 4; for <t>LAPC-4</t> and LNCAP cell lines, n = 3).
    Lapc 4 Blank Cells, supplied by Tree Star Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lapc-4 blank cells/product/Tree Star Inc
    Average 90 stars, based on 1 article reviews
    lapc-4 blank cells - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Immuno-PET imaging of VEGFR-2 expression in prostate cancer with 89 Zr-labeled ramucirumab"

    Article Title: Immuno-PET imaging of VEGFR-2 expression in prostate cancer with 89 Zr-labeled ramucirumab

    Journal: American Journal of Cancer Research

    doi:

    The VEGFR-2 expression in prostate cancer (PrCa) cell lines measured by flow cytometry. The percentage of cell counts are from the same gate of top positive cells in fluorescent intensity in the three PrCa cell lines. Sample groups: Anti-r 2nd Ab only, the controls engaging with Alexa488 anti-rabbit secondary antibody only; Anti-h 2nd Ab only, the controls engaging with Alexa488 anti-human secondary antibody only; 55B11 as 1st Ab, the samples engaging with rabbit anti-human 55B11 as the primary antibody; Df-R as 1st Ab, the samples engaging with deferoxamine-conjugated Ramucirumab as the primary antibody (for PC-3 cell line, n = 4; for LAPC-4 and LNCAP cell lines, n = 3).
    Figure Legend Snippet: The VEGFR-2 expression in prostate cancer (PrCa) cell lines measured by flow cytometry. The percentage of cell counts are from the same gate of top positive cells in fluorescent intensity in the three PrCa cell lines. Sample groups: Anti-r 2nd Ab only, the controls engaging with Alexa488 anti-rabbit secondary antibody only; Anti-h 2nd Ab only, the controls engaging with Alexa488 anti-human secondary antibody only; 55B11 as 1st Ab, the samples engaging with rabbit anti-human 55B11 as the primary antibody; Df-R as 1st Ab, the samples engaging with deferoxamine-conjugated Ramucirumab as the primary antibody (for PC-3 cell line, n = 4; for LAPC-4 and LNCAP cell lines, n = 3).

    Techniques Used: Expressing, Flow Cytometry

    The uptake kinetics of the region of interest (ROI) in the positron emission tomography (PET) images of the three prostate cancer (PrCa) models (for the models bearing PC-3 tumors without/with pre-blockade, n = 3; for the models bearing LAPC-4 and LNCAP tumors, n = 4). P < 0.05.
    Figure Legend Snippet: The uptake kinetics of the region of interest (ROI) in the positron emission tomography (PET) images of the three prostate cancer (PrCa) models (for the models bearing PC-3 tumors without/with pre-blockade, n = 3; for the models bearing LAPC-4 and LNCAP tumors, n = 4). P < 0.05.

    Techniques Used: Positron Emission Tomography

    The typical positron emission tomography (PET) maximum-intensity projections (MIP) of the PC-3 (unblocked/pre-blocked), LNCAP and LAPC-4 prostate cancer (PrCa) models. Arrows point to the xenograft tumor of each group at 96 h p.i.
    Figure Legend Snippet: The typical positron emission tomography (PET) maximum-intensity projections (MIP) of the PC-3 (unblocked/pre-blocked), LNCAP and LAPC-4 prostate cancer (PrCa) models. Arrows point to the xenograft tumor of each group at 96 h p.i.

    Techniques Used: Positron Emission Tomography

    The radioactive ex-vivo bio-distribution in the tumors and major organs of the three prostate cancer (PrCa) models (for the models bearing PC-3 tumors without/with blockade, n = 3; for the models bearing LAPC-4 and LNCAP tumors, n = 4). P < 0.05.
    Figure Legend Snippet: The radioactive ex-vivo bio-distribution in the tumors and major organs of the three prostate cancer (PrCa) models (for the models bearing PC-3 tumors without/with blockade, n = 3; for the models bearing LAPC-4 and LNCAP tumors, n = 4). P < 0.05.

    Techniques Used: Ex Vivo



    Similar Products

    lapc-4 blank cells  (Tree Star Inc)
    90
    Tree Star Inc lapc-4 blank cells
    The VEGFR-2 expression in prostate cancer (PrCa) cell lines measured by flow cytometry. The percentage of cell counts are from the same gate of top positive cells in fluorescent intensity in the three PrCa cell lines. Sample groups: Anti-r 2nd Ab only, the controls engaging with Alexa488 anti-rabbit secondary antibody only; Anti-h 2nd Ab only, the controls engaging with Alexa488 anti-human secondary antibody only; 55B11 as 1st Ab, the samples engaging with rabbit anti-human 55B11 as the primary antibody; Df-R as 1st Ab, the samples engaging with deferoxamine-conjugated Ramucirumab as the primary antibody (for PC-3 cell line, n = 4; for <t>LAPC-4</t> and LNCAP cell lines, n = 3).
    Lapc 4 Blank Cells, supplied by Tree Star Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lapc-4 blank cells/product/Tree Star Inc
    Average 90 stars, based on 1 article reviews
    lapc-4 blank cells - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The VEGFR-2 expression in prostate cancer (PrCa) cell lines measured by flow cytometry. The percentage of cell counts are from the same gate of top positive cells in fluorescent intensity in the three PrCa cell lines. Sample groups: Anti-r 2nd Ab only, the controls engaging with Alexa488 anti-rabbit secondary antibody only; Anti-h 2nd Ab only, the controls engaging with Alexa488 anti-human secondary antibody only; 55B11 as 1st Ab, the samples engaging with rabbit anti-human 55B11 as the primary antibody; Df-R as 1st Ab, the samples engaging with deferoxamine-conjugated Ramucirumab as the primary antibody (for PC-3 cell line, n = 4; for LAPC-4 and LNCAP cell lines, n = 3).

    Journal: American Journal of Cancer Research

    Article Title: Immuno-PET imaging of VEGFR-2 expression in prostate cancer with 89 Zr-labeled ramucirumab

    doi:

    Figure Lengend Snippet: The VEGFR-2 expression in prostate cancer (PrCa) cell lines measured by flow cytometry. The percentage of cell counts are from the same gate of top positive cells in fluorescent intensity in the three PrCa cell lines. Sample groups: Anti-r 2nd Ab only, the controls engaging with Alexa488 anti-rabbit secondary antibody only; Anti-h 2nd Ab only, the controls engaging with Alexa488 anti-human secondary antibody only; 55B11 as 1st Ab, the samples engaging with rabbit anti-human 55B11 as the primary antibody; Df-R as 1st Ab, the samples engaging with deferoxamine-conjugated Ramucirumab as the primary antibody (for PC-3 cell line, n = 4; for LAPC-4 and LNCAP cell lines, n = 3).

    Article Snippet: X.0.7; Tree Star, Inc.; Ashland, OR), shift values of the top 1% of the positive counts in fluorescent intensity were gated on the histograms of LAPC-4 blank cells as the baseline control.

    Techniques: Expressing, Flow Cytometry

    The uptake kinetics of the region of interest (ROI) in the positron emission tomography (PET) images of the three prostate cancer (PrCa) models (for the models bearing PC-3 tumors without/with pre-blockade, n = 3; for the models bearing LAPC-4 and LNCAP tumors, n = 4). P < 0.05.

    Journal: American Journal of Cancer Research

    Article Title: Immuno-PET imaging of VEGFR-2 expression in prostate cancer with 89 Zr-labeled ramucirumab

    doi:

    Figure Lengend Snippet: The uptake kinetics of the region of interest (ROI) in the positron emission tomography (PET) images of the three prostate cancer (PrCa) models (for the models bearing PC-3 tumors without/with pre-blockade, n = 3; for the models bearing LAPC-4 and LNCAP tumors, n = 4). P < 0.05.

    Article Snippet: X.0.7; Tree Star, Inc.; Ashland, OR), shift values of the top 1% of the positive counts in fluorescent intensity were gated on the histograms of LAPC-4 blank cells as the baseline control.

    Techniques: Positron Emission Tomography

    The typical positron emission tomography (PET) maximum-intensity projections (MIP) of the PC-3 (unblocked/pre-blocked), LNCAP and LAPC-4 prostate cancer (PrCa) models. Arrows point to the xenograft tumor of each group at 96 h p.i.

    Journal: American Journal of Cancer Research

    Article Title: Immuno-PET imaging of VEGFR-2 expression in prostate cancer with 89 Zr-labeled ramucirumab

    doi:

    Figure Lengend Snippet: The typical positron emission tomography (PET) maximum-intensity projections (MIP) of the PC-3 (unblocked/pre-blocked), LNCAP and LAPC-4 prostate cancer (PrCa) models. Arrows point to the xenograft tumor of each group at 96 h p.i.

    Article Snippet: X.0.7; Tree Star, Inc.; Ashland, OR), shift values of the top 1% of the positive counts in fluorescent intensity were gated on the histograms of LAPC-4 blank cells as the baseline control.

    Techniques: Positron Emission Tomography

    The radioactive ex-vivo bio-distribution in the tumors and major organs of the three prostate cancer (PrCa) models (for the models bearing PC-3 tumors without/with blockade, n = 3; for the models bearing LAPC-4 and LNCAP tumors, n = 4). P < 0.05.

    Journal: American Journal of Cancer Research

    Article Title: Immuno-PET imaging of VEGFR-2 expression in prostate cancer with 89 Zr-labeled ramucirumab

    doi:

    Figure Lengend Snippet: The radioactive ex-vivo bio-distribution in the tumors and major organs of the three prostate cancer (PrCa) models (for the models bearing PC-3 tumors without/with blockade, n = 3; for the models bearing LAPC-4 and LNCAP tumors, n = 4). P < 0.05.

    Article Snippet: X.0.7; Tree Star, Inc.; Ashland, OR), shift values of the top 1% of the positive counts in fluorescent intensity were gated on the histograms of LAPC-4 blank cells as the baseline control.

    Techniques: Ex Vivo